Biotech entity
All 3 tracked stories fall under one category: pharma. Jefferies Financial Group is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. The 5 average consequence score is below the beat benchmark of 6.1 in the same window.
Last mentioned: 8h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: pharma. Jefferies Financial Group is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. The 171-day window averages about 0.1 stories each week. We currently track 3 Biotech stories that mention Citigroup, published between February 21, 2026 and August 10, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 669 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Citigroup. Shared-story counts are live from our verified record — not editorial picks.
Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Source: tickerreport.com · dailypolitical.com
Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Source: Ticker Report · Watch List News
Wells Fargo has upgraded AxoGen (NASDAQ: AXGN) to a 'Strong-Buy' rating, reflecting growing institutional confidence in the company's leadership in peripheral nerve repair. The upgrade follows a significant price target increase from Jefferies and a reaffirmed 'Market Outperform' rating from Citigroup.
Citigroup is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
